Multiple suitors are competing for a biopharmaceutical services provider worth about $9 billion, including debt, a $5.81 billion stake in a South Korean automotive supplier is up for grabs, and EssilorLuxottica may sue GrandVision over their potentially broken deal. Here, Law360 breaks down these and other deal rumors from the past week that you need to be aware of.